Mersana Therapeutics, Inc.
MRSN
$0.315
-$0.065-17.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 59.69% | 62.13% | 51.31% | 36.74% | 15.94% |
| Total Depreciation and Amortization | 7.32% | 23.89% | 49.38% | 55.72% | 63.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.33% | -25.07% | -29.79% | -21.75% | -15.11% |
| Change in Net Operating Assets | -63.82% | -159.23% | -145.17% | -149.11% | -114.40% |
| Cash from Operations | 51.24% | 49.48% | -51.54% | -145.03% | -242.12% |
| Capital Expenditure | 93.91% | 79.82% | 60.73% | 50.02% | 1.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -90.52% | -131.47% | 191.24% | 131.93% | 181.09% |
| Cash from Investing | -90.46% | -133.91% | 186.25% | 130.43% | 178.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -751.15% | 22.99% | 6.90% | -0.38% | 3.68% |
| Issuance of Common Stock | -93.36% | -95.42% | -95.75% | -30.79% | -37.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | 100.00% | -- |
| Cash from Financing | -95.68% | -95.55% | -95.96% | -30.85% | -38.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.27% | -4,980.28% | -955.62% | 55.57% | 193.10% |